| 5-HTP (5-Hydroxytryptophan)
vs. Prozac (SSRIs)
by Ward Dean, MD, James South, MA, and Jim English
Neurotransmitters are specialized biochemicals
that nerve cells use to 'talk' to each other. Serotonin is one of
some ten major brain neurotransmitters. Deficiencies of serotonin
in the brain have been linked to a number of disparate conditions,
including: depression (especially the agitated, anxious, irritable
type), (1-6) anxiety, (7) suicide, (8) alcoholism, (9) violent behavior,
(8) PMS, (10) obesity, (10,11) compulsive gambling, (12) insomnia,
(13) carbohydrate craving, (10) SAD (seasonal affective disorder),
(10) and migraine headaches. (14)
Serotonin nerve circuits promote feelings of well-being,
calmness, personal security, relaxation, confidence and concentration.
(15) Serotonin circuits also help counterbalance the tendency of
two other major neurotransmitters in the brain — dopamine
and noradrenaline — to encourage overarousal, fear, anger,
tension, aggression, violence, obsessive-compulsive actions, overeating,
anxiety and sleep disturbances. (15) Many people suffer from various
degrees of brain serotonin deficiency, leading to a host of mental,
emotional and behavioral problems. To understand why brain serotonin
deficiency is becoming more common in modern society, it is necessary
to look at how the brain makes serotonin.
Serotonin (5HT), dopamine, and noradrenaline are the three main
'monoamine' neurotransmitters — 'mono' because each one is
made from a single, specific amino acid. Serotonin is made from
tryptophan, while dopamine and noradrenaline are made from tyrosine
and phenylalanine. Since the blood-brain barrier prevents serotonin
from being 'imported' from outside the brain, all serotonin used
by our brain cells must be made within the neurons. Normally the
blood-brain barrier serves as a protective device to prevent toxins
from entering the brain. But this protection comes at a price —
even 'friendly' molecules, such as amino acids needed by the brain,
are limited by this barrier.
When nutrients are allowed to cross the blood-brain
barrier they must be 'ferried' by specialized transport molecules,
much as passengers being transported on a bus. This process creates
a special 'bottleneck' for serotonin. Serotonin itself cannot pass
through the blood-brain barrier, while its precursor, tryptophan,
must share its transport 'bus' with five other amino acids —
leucine, isoleucine, valine, tyrosine and phenylalanine.
In any normal diet, animal protein-based or vegetarian,
tryptophan is the least plentiful of all 20 food amino acids. Thus,
tryptophan is typically outnumbered as much as 9:1 in its competition
to secure its transport through the blood-brain barrier into the
brain. Eating a high-protein diet in an attempt to increase dietary
tryptophan (a typical diet provides only 1-1.5 grams/day) only increases
its competition even more. Ironically, the only dietary strategy
that increases brain tryptophan supply is a high-carbohydrate, low-protein
diet. When large amounts of carbohydrates are eaten, the body secretes
large amounts of the hormone insulin to lower the resulting high
blood sugar. In addition to lowering blood sugar levels, insulin
also clears most of the five amino acids that compete with tryptophan
for a 'ride' to the brain. The result is that tryptophan has the
'bus' to itself, allowing plenty of tryptophan to reach the brain.
(10)
This dietary strategy is instinctively known and practiced by many
Americans who eat large amounts of carbohydrates, including candy,
cake, pie, bread, chips, ice cream, etc., when they are feeling
stressed, depressed or anxious. The resulting increase in brain
serotonin levels suppresses arousal and anxiety, and promotes a
(temporary) sense of well-being and security. Unfortunately, this
strategy comes at a high price. The same insulin which enhances
brain serotonin levels also increases the conversion of the fats,
carbohydrates and amino acids cleared from the blood into stored
body fat! Hence the carbohydrate addiction/ obesity/serotonin connection.
(10)
In the 1970s, the American health food industry began to provide
an alternative method of getting more tryptophan to the brain --
tryptophan supplements. Many people found that 500 to 3,000 mg of
supplementary tryptophan daily provided practical relief from depression,
PMS, insomnia and obsessive-compulsive disorders. In 1989, the FDA
removed tryptophan from the American health food market due to a
mysterious outbreak of a rare but serious ailment -- eosinophilia
myalgia (EMS). This EMS 'epidemic' was later traced to a single
batch of contaminated tryptophan from a Japanese producer. Thirteen
years later, although tryptophan has been proven to be safe (and
is currently available in baby food formulas, intravenous feeding
solutions, and veterinary products) the FDA still shows no signs
of allowing tryptophan back onto the market as a dietary supplement.
Fortunately, a safe, natural and effective alternative
to tryptophan has been researched for over 30 years. This substance
is L-5-Hydroxytryptophan (5-HTP). 5-HTP is not produced by bacterial
fermentation (as was the tainted tryptophan) nor chemical synthesis,
but is extracted from the seeds of the Griffonia plant.
When neurons convert tryptophan into serotonin, they must first
use a vitamin B3-dependent enzyme to convert tryptophan into 5-HTP.
A vitamin B6-dependent enzyme is then used to convert 5-HTP into
serotonin. One researcher noted, 'There are several advantages of
considering L-5-HTP, as opposed to L-tryptophan, as being the major
determinant in elevating brain serotonin levels: L-5-HTP is not
degraded by tryptophan pyrrolase to kynurenine, the major pathway
for peripheral degradation of L-tryptophan (about 98 percent).
Furthermore, L-5-HTP easily crosses the blood-brain
barrier ...' (1) Additionally, it should be noted that 5-HTP is
not incorporated into proteins, as is tryptophan; nor is 5-HTP used
to make vitamin B3, as is tryptophan. Thus, in comparison to tryptophan,
5-HTP is virtually a 'guided missile' that is directly targeted
to increasing brain serotonin levels. Strikingly, some studies have
shown better results using 200 to 300 mg of 5-HTP per day as an
antidepressant than other studies using 2000 to 3,000 mg or more
of tryptophan per day. (17)
A placebo-controlled, double-blind study reported
in 1992 found excellent results treating obesity using doses of
5-HTP as high as 900 mg daily, with minimal side effects (the greatest
side effect being diarrhea or upset stomach)! (11) In one study,
the antidepressant effects of 5-HTP was compared with fluvoxamine,
a prescription Prozac-like drug used in Europe. The 5-HTP patients
showed slightly better treatment response than the fluvoxamine group,
yet had significantly fewer and less severe side effects. The researchers
note: 'Regarding tolerance and safety, however, oxitriptan [5-HTP]
proved superior to fluvoxamine as was apparent from a marked difference
in severity of untoward side effects between the two compounds.
The study presented here ...strongly confirm[s] the efficacy of
5-HTP as an antidepressant.' (4)
In a society that has made the book Listening to Prozac
a mega-bestseller, some may still consider serotonin-selective re-uptake
inhibitor (SSRI) drugs such as Prozac the 'gold standard' of managing
the serotonin-deficiency syndrome, even though the Poeldinger study
showed 5-HTP to be superior to a major SSRI, fluvoxamine. A study
reported by Risch and Nemeroff demonstrates, however, that even
those 'successfully' treated with SSRIs (ignoring their frequent
and sometimes serious side effects) are dependent upon their brains’
producing adequate serotonin from either tryptophan or 5-HTP.
SSRIs work by conserving existing brain serotonin
supplies by keeping more serotonin in the synaptic gap between neurons.
They achieve this through preventing enzymatic degradation of synaptic
serotonin. SSRIs do not enhance serotonin production. Risch and
Nemeroff state: "...depressed patients were treated with low-tryptophan
diets that were supplemented with high doses of neutral amino acids
[which compete with tryptophan for transport through the blood-brain
barrier]... Remitted depressed subjects receiving serotonergic antidepressants
(e.g. fluoxetine [Prozac], fluvoxamine) who were challenged with
low-tryptophan diet supplemented with neutral amino acids promptly
relapsed into severe clinical depression. When the tryptophan supplementation
was provided, the patients promptly recovered..." (3)
The many successful published studies using 5-HTP
show that 5-HTP, by naturally elevating brain serotonin, can alleviate
the serotonin-deficiency syndrome without any help from SSRI drugs.
Yet the study related by Risch and Nemeroff eloquently shows that
the success of SSRI drugs is crucially dependent upon the brain
producing adequate serotonin (from either tryptophan or 5-HTP),
and that brain serotonin production is the controlling or rate-limiting
variable underlying the apparent success of SSRIs. It appears that
the more logical and economically sound choice to alleviate conditions
that result from the serotonin deficiency syndrome is 5-HTP, the
immediate precursor of the deficient substance.
References
1. K. Zmilacher, et al. L-5-Hydroxytryptophan
Alone and in Combination with a Peripheral Decarboxylase Inhibitor
in the Treatment of Depression. Neuropsychobiology. 1988; 20: 28-35.
2. W. Byerley, et al. 5-Hydroxytryptophan: A Review of Its Antidepressant
Efficacy and Adverse Effects. J Clin Psychopharmacol 1987; 7: 127-37.
3. S. Risch and C. Nemeroff. Neurochemical Alterations of Serotonergic
Neuronal Systems in Depression. J Clin Psychiatry. 1992; 53: 3-7.
4. W. Poeldinger, et al. A Functional-Dimensional Approach to Depression:
Serotonin Deficiency as a Target Syndrome in a Comparison of 5 -Hydroxytryptophan
and Fluvoxamine. Psychopathology. 1991; 24: 53-81.
5. H. van Praag. Management of Depression with Serotonin Precursors.
Biol Psychiatry. 1981; 16: 291-310.
6. S Takahashi, et al. Effect of L-5-Hydroxytryptophan on Brain
Monoamine Metabolism and Evaluation of Its Clinical Effect in Depressed
Patients. Psychiat Res 1975; 12: 177-87.
7. R. Kahn and H. Westenberg. L-5-Hydroxytryptophan in the Treatment
of Anxiety Disorders. J Affect Disord, 1985; 8: 197-200.
8. V. Linnoila and M. Virkkunen. Aggression, Suicidality, and Serotonin.
J Clin Psychiatry. 1992; 53: 46-51.
9. L. Buydens-Branchey, et al. Age of Alcoholism Onset. II. Relationship
to Susceptibility to Serotonin Precursor Availability. Arch Gen
Psychiatry. 1989; 46: 231-36.
10. J. Wurtman. Carbohydrate Craving, Mood Changes and Obesity.
J Clin Psychiatry. 1988; 49: 37-39.
11. C. Cangiano, et al. Eating Behavior and Adherence to Dietary
Prescriptions in Obese Adult Subjects Treated with 5-Hydroxytryptophan.
Am J Clin Nutr 1992; 56: 863-7.
12. D. Murphy et al. Obssessive-Compulsive Disorder as a 5-HT Subsytem
-Related Behavioral Disorder. Bri J Psychiatry. 1989; 155: 15-24.
13. C. Maurizi. The Therapeutic Potential for Tryptophan and Melatonin:
Possible Roles in Depression, Sleep, Alzheimer’s Disease and
Abnormal Aging. Med Hypoth. 1990; 31: 233-42.
14. G. DeBenedittis and R. Massei. 5-HT Precursors in Migraine Prophy
laxis: A Double-Blind Cross-Over Study with L-5-Hydroxytryptophan
versus Placebo. Clin J Pain. 1986; 3: 123-29.
15. J. Robertson and T. Monte. Natural Prozac-Learning to Release
Your Body’s Own Anti-Depressants. San Francisco: Harper; 1997.
16. A. Gaby. B6-The Natural Healer. New Canaan: Keats: 1984.
17. H. van Praag. Studies of the Mechanism of Action of Serotonin
Precursors in Depression. Psychopharmacol Bull. 1984; 20: 599-602.
18. P. Hartvig et al. Pyridoxine Effect on Synthesis Rate of Serotonin
in the Monkey Brain Measured with Positron Emission Tomography.
J Neural Trans. 1995; 102: 91-7.
19. K. Dakshinamurti, et al. Influence of B Vitamins on Binding
Properties of Serotonin Receptors in CNS of Rats. Klin Wochenschr.
1990; 68: 142-45.
20. M. Jacobsen, et al. Cardiac Manifestations in Mid-gut Carcinoid
Disease. Eur Heart J. 1995; 16: 263-68.
21. Y. Hoshino, et al. Serum Serotonin Levels of Normal Subjects
in Physiological State and Stress Conditions. Jpn J Psychosom Med.
1979; 19: 283-93.
22. H. van Praag. Central Monoamine Metabolism in Depressions. I.
Serotonin and Related Compounds. Compreh Psychiatry. 1980; 21: 30-43.
23. T. Li Kam Wa, et al. Blood and Urine 5-Hydroxytryptamine [Serotonin]
Levels after Administration of Two 5-Hydroxytryptophan Precursors
in Normal Man. Bri J Clin Pharmacol. 1995; 39:327-29.
24. G. Huether, et al. The Metabolic Fate of Infused L-Tryptophan
in Men: Possible Clinical Implications of the Accumulation of Circulating
Tryptophan and Tryptophan Metabolites. Psychopharmacol (Germany).
1992; 109: 442-32.
25. K. Tornebrandt, et al. Heart Involvement in Metastatic Carcinoid
Disease. Clin Cardiol. 1986; 9 (1).
26. R. Arora and R. Warner. Do Indole Markers Predict Carcinoid
Heart Disease? Chest. 1986; 90: 87-9.
27. M. Werbach. Nutritional Influences on Illness, 2nd ed. ‘Atherosclerosis,’
57-102. Tarzana, CA: Third Line Press; 1996.
28. P. Turlapaty and B. Altura. Magnesium Deficiency Produces Spasms
of Coronary Arteries: Relationship to Etiology of Sudden Death Ischemic
Heart Disease. Science. 1980; 208: 198-200.
|